Table 2.
Variables | Subcluster | Subcluster | Subcluster | Subcluster | P value |
---|---|---|---|---|---|
X1 | X2 | Y1 | Y2 | ||
n (%) | n (%) | n (%) | n (%) | ||
Total No of patients | 24 (23.0) | 28 (27.0) | 24 (23.0) | 28 (27.0) | |
Mean age | 64 | 75.5 | 70.5 | 69 | |
No female | 2 | 4 | 5 | 1 | |
Grade | |||||
G1 | 10 (41.7) | 13 (46.4) | 19 (79.2) | 18 (64.3) | <0.001* |
G2-3 | 14 (58.3) | 15 (53.6) | 5 (12.5) | 10 (21.4) | |
Stage | |||||
Ta | 16 (66.7) | 15 (53.6) | 19 (79.2) | 20 (71.4) | ns* |
T1 | 3 (12.5) | 8 (28.6) | 5 (20.8) | 5 (17.9) | |
T2–T4 | 5 (20.8) | 5 (17.8) | 0 | 3 (10.7) | |
Smoking history | |||||
Current and ex | 24 (100) | 26 (92.9) | 22 (91.7) | 27 (96.4) | ns** |
Never | 0 | 2 (7.1) | 2(8.3) | 1 (3.6) | |
Occupational exp. | |||||
Yes | 9 (37.5) | 9 (32.1) | 9 (37.5) | 12 (42.9) | ns** |
No | 15 (62.5) | 19 (67.9) | 15 (62.5) | 16 (57.1) | |
No of tumors | |||||
1 | 18 (75.0) | 18 (64.3) | 17 (63.0) | 21 (75.0) | ns* |
>1 | 6 (25.0) | 10 (35.7) | 7 (37.0) | 7 (25.0) | |
Tumor diameter | |||||
2 cm | 10 (41.7) | 7 (25.0) | 19 (79.2) | 18 (64.3) | <0.001* |
>2 cm | 14 (58.3) | 21 (75.0) | 5 (20.8) | 10 (35.7) | |
Local recurrence | |||||
Yes | 5 (21.0) | 7 (25.0) | 7 (29.2) | 5 (17.9) | ns** |
No | 19 (79.0) | 21 (75.0) | 17 (70.8) | 23 (82.1) | |
HPV infection | |||||
Yes | 4 (16.6) | 4 (14.3) | 3 (12.5) | 3 (10.7) | ns** |
No | 20 (83.4) | 24 (85.7) | 21 (87.5) | 25 (89.3) | |
CHEK2 mutation | |||||
Yes | 2 (8.3) | 1 (3.6) | 1 (4.2) | 3 (10.7) | ns** |
No | 22 (91.7) | 27 (96.4) | 23 (95.8) | 25 (89.3) | |
FGFR3 mutation | |||||
Yes | 1 (4.2) | 1 (3.6) | 9 (37.5) | 28 (100) | <0.001** |
No | 23 (95.8) | 27 (96.4) | 15 (62.5) | 0 | |
TP53 mutation | |||||
Yes | 5 (20.8) | 5 (17.9) | 0 | 5 (17.9) | ns** |
No | 19 (79.2) | 23 (82.1) | 24 (100) | 23 (82.10 | |
TP53 expression | |||||
Altered | 1 (4.2) | 16 (57.1) | 1 (4.2) | 11 (39.3) | <0.01** |
Normal | 23 (95.8) | 12 (42.9) | 23 (95.8) | 17 (60.7) | |
LOH chromosome 9 | |||||
Yes | 1 (4.2) | 17 (60.7) | 7 (37.0) | 8 (28.6) | <0.001** |
No | 23 (95.8) | 11 (39.3) | 17 (63.0) | 20 (71.4) | |
LOH chromosome 13 | |||||
Yes | 1 (4.2) | 3 (10.7) | 2 (8.3) | 0 | ns** |
No | 23 (95.8) | 25 (89.3) | 22 (91.7) | 28 (100) | |
LOH chromosome 17 | |||||
Yes | 2 (8.3) | 8 (28.6) | 0 | 2 (7.1) | <0.01** |
No | 22 (91.7) | 20 (71.4) | 24 (100) | 26 (92.9) | |
UroVysion test | |||||
Positive | 24 (100) | 26 (92.9) | 0 | 24 (85.7) | <0.001** |
Negative | 0 | 2 (7.1) | 24 (100) | 4 (14.3) | |
CDKN2A polymorphism | |||||
Ala/Thr | 5 (20.8) | 1 (3.6) | 1 (4.2) | 0 | <0.05** |
Ala/Ala | 19 (79.2) | 27 (96.4) | 23 (95.8) | 28 (100) | |
CYP1B1 polymorphism | |||||
355T/T | 5 (20.8) | 3 (10.7) | 1 (4.2) | 5 (17.9) | ns** |
355T/T and T/G | 19 (79.2) | 25 (89.3) | 23 (95.8) | 23 (82.1) | |
TP53 polymorphism | |||||
Arg | 16 (66.6) | 15 (53.6) | 13 (54.2) | 11 (39.3) | ns** |
Arg/Pro | 7 (29.2) | 12 (42.9) | 9 (37.5) | 13 (46.4) | |
Pro | 1 (4.2) | 1 (3.5) | 2 (8.3) | 4 (14.3) |